Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $9.00. The company’s shares closed last Thursday at $8.51.
According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -1.0% and a 35.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Neoleukin Therapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $12.75, which is a 47.9% upside from current levels. In a report released today, Leerink Partners also maintained a Hold rating on the stock with a $10.00 price target.
The company has a one-year high of $13.40 and a one-year low of $0.71. Currently, Adaptimmune Therapeutics has an average volume of 3.17M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADAP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.